Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · see citing works

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261 · see citing works

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS

Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236 · see citing works

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453 · see citing works

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378 · see citing works

Stimulation of Bone Formation in Vitro and in Rodents by Statins

Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776 · see citing works

Statin-associated myopathy

Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463 · see citing works

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796 · see citing works

Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences

Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527 · see citing works

Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization

Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344 · see citing works

Gemfibrozil greatly increases plasma concentrations of cerivastatin

Backman, J. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 337 · see citing works

Effect of itraconazole on the pharmacokinetics of atorvastatin*

Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300 · see citing works

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 285 · see citing works

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*

Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90034-0 · Cited by 275 · see citing works

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264 · see citing works

Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin

Jacobsen, W., Kuhn, B., Soldner, A., Kirchner, G. I., Sewing, K.-F., Kollman, P. A., Benet, L. Z., & Christians, U. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15086-6 · Cited by 236 · see citing works

Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients

Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 220 · see citing works

HMG‐CoA reductase inhibitors and P‐glycoprotein modulation

Bogman, K., Peyer, A., Török, M., Küsters, E., & Drewe, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703920 · Cited by 194 · see citing works

Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human Osteoblasts

Ohnaka, K., Shimoda, S., Nawata, H., Shimokawa, H., Kaibuchi, K., Iwamoto, Y., & Takayanagi, R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5597 · Cited by 191 · see citing works

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191 · see citing works

Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes

Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189 · see citing works

Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P-Glycoprotein-Mediated Secretion

Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., & Whitfield, L. R. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008612 · Cited by 179 · see citing works

Drug Interactions with Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation with CYP3A

Ma, B., Prueksaritanont, T., & Lin, J. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15118-5 · Cited by 177 · see citing works

HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein

Wang, E., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011036428972 · Cited by 176 · see citing works

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

Transon, C., Leemann, T., & Dayer, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050094 · Cited by 173 · see citing works

The Effect of Statins on mRNA Levels of Genes Related to Inflammation, Coagulation, and Vascular Constriction in HUVEC.

Morikawa, S., Takabe, W., Mataki, C., Kanke, T., Itoh, T., Wada, Y., Izumi, A., Saitō, Y., Hamakubo, T., & Kodama, T. (2002) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9.178 · Cited by 167 · see citing works

The 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions

Fischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 148 · see citing works

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139 · see citing works

Clinical Pharmacokinetics of Cerivastatin

ck, W. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00002 · Cited by 122 · see citing works

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

Saitō, Y., Yamada, N., Teramoto, T., Itakura, H., Yoshiya, H. A. T. A., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., & Ogawa, N. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00712-2 · Cited by 114 · see citing works

Biotransformation of pravastatin sodium in humans.

Everett, D. W., Chando, T. J., DiDonato, G. C., Singhvi, S. M., Pan, H., & Weinstein, S. H. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08889-0 · Cited by 112 · see citing works

Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

Siedlik, P. H., Olson, S. C., Yang, B., & Stern, R. H. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900510 · Cited by 110 · see citing works

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

Transon, C., Leemann, T., Vogt, N., & Dayer, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90054-3 · Cited by 105 · see citing works

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

POGSON, G. W., Kindred, L. H., & Carper, B. G. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00034-x · Cited by 105 · see citing works

Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Aoki, T., Nishimura, H., Nakagawa, S., Kojima, J., Suzuki, H., Tamaki, T., Wada, Y., Yokoo, N., Sato, F., KIMATA, H., et al. (1997) · PubMed · Cited by 104 · see citing works

Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin

Igel, M., Sudhop, T., & von Bergmann, K. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401102731 · Cited by 100 · see citing works

Safety considerations for statins

Bolego, C., Baetta, R., Bellosta, S., Corsini, A., & Paoletti, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00007 · Cited by 98 · see citing works

Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

Fujino, H., Yamada, I., Shimada, S., Yoneda, M., & Kojima, J. (2003) · Xenobiotica · doi:10.1080/0049825021000017957 · Cited by 96 · see citing works

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

Suzuki, M., Iwasaki, H., Fujikawa, Y., Kitahara, M., Sakashita, M., & Sakoda, R. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00198-5 · Cited by 87 · see citing works

NK-104: a novel synthetic HMG-CoA reductase inhibitor

Kajinami, K., Mabuchi, H., & Saito, Y. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.11.2653 · Cited by 85 · see citing works

Relative Induction of mRNA for HMG CoA Reductase and LDL Receptor by Five Different HMG-CoA Reductase Inhibitors in Cultured Human Cells

Morikawa, S., Umetani, M., Nakagawa, S., Yamazaki, H., Suganami, H., Inoue, K., Kitahara, M., Hamakubo, T., Kodama, T., & Saitō, Y. (2000) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.7.138 · Cited by 76 · see citing works

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

Noji, Y., Higashikata, T., Inazu, A., Nohara, A., Ueda, K., Miyamoto, S., Kajinami, K., Takegoshi, T., Koizumi, J., & Mabuchi, H. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00765-1 · Cited by 74 · see citing works

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia

Kajinami, K., Koizumi, J., Ueda, K., Miyamoto, S., Takegoshi, T., & Mabuchi, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00656-6 · Cited by 68 · see citing works

Clinical Efficacy of Pitavastatin, a New 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, in Patients with Hyperlipidemia

Saitō, Y., Yamada, N., Teramoto, T., Itakura, H., Yoshiya, H. A. T. A., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., Goto, Y., et al. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1299888 · Cited by 66 · see citing works

Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs

Suzuki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00146-x · Cited by 65 · see citing works

Simvastatin and lovastatin, but not pravastatin, interact with MDR1

Sakaeda, T., Takara, K., Kakumoto, M., Ohmoto, N., Nakamura, T., Iwaki, K., Tanigawara, Y., & Okumura, K. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778493 · Cited by 52 · see citing works

Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (1) : Absorption, Distribution, Metabolism and Excretion in Rats

KIMATA, H., Fujino, H., Koide, T., Yamada, Y. M. A., Tsunenari, Y., & Yanagawa, Y. (1998) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.13.484 · Cited by 51 · see citing works

Plaque-Stabilizing Effect of Pitavastatin in Watanabe Heritable Hyperlipidemic(WHHL) Rabbits.

Suzuki, H., Hideyuki, K., Sato, F., Yonemitsu, Y., Nakashima, Y., & Sueishi, K. (2003) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10.109 · Cited by 47 · see citing works

Quantitative Distinctions of Active Site Molecular Recognition by P-Glycoprotein and Cytochrome P450 3A4

Wang, E., Lew, K., Barecki-Roach, M., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010125x · Cited by 47 · see citing works

HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

Sone, H., Takahashi, A., Shimano, H., Ishibashi, S., Yoshino, G., Morisaki, N., Saitō, Y., Kawazu, S., Teramoto, T., Fujita, T., et al. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02038-6 · Cited by 45 · see citing works

Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (4). Interspecies Variation in Laboratory Animals and Humans.

Fujino, H., Kojima, J., Yamada, Y., Kanda, H., & KIMATA, H. (1999) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.14.79 · Cited by 37 · see citing works

Inhibition of Migration and Proliferation of Rat Vascular Smooth Muscle Cells by a New HMG-CoA Reductase Inhibitor, Pitavastatin

Kohno, M., Shinomiya, K., Abe, S., Noma, T., Kondô, I., Oshita, A., Takeuchi, H., TAKAGI, Y., Yukiiri, K., Mizushige, K., et al. (2002) · Hypertension Research · doi:10.1291/hypres.25.279 · Cited by 35 · see citing works

Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (5). In Vitro Metabolism and Plasma Protein Binding in Animals and Human.

Fujino, H., Yamada, I., Kojima, J., Hirano, M., Matsumoto, H., & Yoneda, M. (1999) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.14.415 · Cited by 35 · see citing works

NK-104, a Newly Developed HMG-CoA Reductase Inhibitor, Suppresses Neointimal Thickening by Inhibiting Smooth Muscle Cell Growth and Fibronectin Production in Balloon-Injured Rabbit Carotid Artery

Kitahara, M., Kanaki, T., Toyoda, K., Miyakoshi, C., Tanaka, S., Tamaki, T., & Saitō, Y. (1998) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.77.117 · Cited by 35 · see citing works

NK‐104, a 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells

Takemoto, M., Kitahara, M., Yokote, K., Asaumi, S., Take, A., Saitō, Y., & Mori, S. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704046 · Cited by 28 · see citing works

Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase—Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr 1a/b Gene Disruption on Tissue Distribution in Mice

Fujino, H., Yamada, I., Shimada, S., & Kojima, J. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.449 · Cited by 27 · see citing works

Pitavastatin Inhibits Vascular Smooth Muscle Cell Proliferation by Inactivating Extracellular Signal-Regulated Kinases 1/2.

Yamakawa, T., Tanaka, S., Kamei, J., Kadonosono, K., & Okuda, K. (2003) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10.37 · Cited by 27 · see citing works

Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay — inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase

Fujino, H., Yamada, I., Shimada, S., & Yoneda, M. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00141-4 · Cited by 25 · see citing works

First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104

Suzuki, M., Yanagawa, Y., Iwasaki, H., Kanda, H., Yanagihara, K., Matsumoto, H., Ohara, Y., Yazaki, Y., & Sakoda, R. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00519-3 · Cited by 23 · see citing works

INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL

Fujino, H., Yamada, I., Shimada, S., Hirano, M., Tsunenari, Y., & Kojima, J. (2003) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2003.19.3.161 · Cited by 23 · see citing works

NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells

Yanagita, T., Hara, E., Yotsumoto, H., Rahman, S. M., Han, S.-Y., Cha, J.-Y., & Yamamoto, K. (1999) · Current Therapeutic Research · doi:10.1016/s0011-393x(99)80021-6 · Cited by 20 · see citing works

Interaction between Several Medicines and Statins

Fujino, H., Saito, T., Tsunenari, Y., & Kojima, J. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1297087 · Cited by 20 · see citing works

Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia

Aoki, T., Yoshinaka, Y., Yamazaki, H., Suzuki, H., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01547-9 · Cited by 19 · see citing works

NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells

Ooyen, C., Zecca, A., Bersino, A. M., & Catapano, A. L. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00018-0 · Cited by 17 · see citing works

Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs.

Kojima, J., OHSHIMA, T., Yoneda, M., & Sawada, H. (2001) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.16.497 · Cited by 14 · see citing works

Synthesis of piperazine derivatives and evaluation of their antihistamine and antibradykinin effects

Choo, H. P., Chung, B., & Chung, S.-H. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00471-0 · Cited by 13 · see citing works

Hypolipidemic Effect of NK-104 and Other 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Guinea Pigs

Suzuki, H., Yamazaki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300000 · Cited by 12 · see citing works

Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver

Yamamoto, K., Todaka, N., Goto, H., Jayasooriya, A. P., Sakono, M., Ogawa, Y., & Fukuda, N. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00390-2 · Cited by 9 · see citing works

Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia

Teramoto, T., Saito, Y., & Nakaya, N. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80238-5 · Cited by 9 · see citing works

New Nomenclature of Human ABC Transporter Genes.

Ishikawa, T., ALLIKIMETS, R., Dean, M. C., Higgins, C. F., Ling, V. W. T., & Wain, H. (2000) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.15.8 · Cited by 7 · see citing works

Cholesterol-lowering Effect of NK-104, a 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitor, in Guinea Pig Model of Hyperlipidemia

Aoki, T., Yamazaki, H., Suzuki, H., Tamaki, T., Sato, F., Kitahar, M., & Saitō, Y. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300025 · Cited by 6 · see citing works

Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia — Randomized double-blind, cross-over placebo controlled study

Sasaki, J., Ikeda, Y., Yamamoto, K., Ageta, M., & Arakawa, K. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80335-4 · Cited by 5 · see citing works

Triglyceride-lowering Effect of Pitavastatin in a Guinea Pig Model of Postprandial Lipemia

Aoki, T., Yamazaki, H., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1297088 · Cited by 5 · see citing works

Natural products to drugs: natural product-derived compounds in clinical trials

Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,073 · see citing works

Natural products to drugs: natural product derived compounds in clinical trials

Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 493 · see citing works

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans

Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 444 · see citing works

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 339 · see citing works

DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1

Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302 · see citing works

Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin

Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256 · see citing works

Statins and breast cancer prognosis: evidence and opportunities

Ahern, T. P., Lash, T. L., Damkier, P., Christiansen, P., & Cronin-Fenton, D. P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70119-6 · Cited by 203 · see citing works

Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System

McFarland, A. J., Anoopkumar‐Dukie, S., Arora, D. S., Grant, G. D., McDermott, C., Perkins, A. V., & Davey, A. K. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120607 · Cited by 199 · see citing works

Literature Mining for the Discovery of Hidden Connections between Drugs, Genes and Diseases

Frijters, R., van Vugt, M. J. H., Smeets, R. L., van Schaik, R., de Vlieg, J., & Alkema, W. B. L. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000943 · Cited by 161 · see citing works

Pitavastatin

Mukhtar, R., Reid, J., & Reckless, J. P. D. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00461.x · Cited by 156 · see citing works

Association of active γ-secretase complex with lipid rafts

Urano, Y., Hayashi, I., Isoo, N., Reid, P., Shibasaki, Y., Noguchi, N., Tomita, T., Iwatsubo, T., Hamakubo, T., & Kodama, T. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400333-jlr200 · Cited by 143 · see citing works

A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance

Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 109 · see citing works

Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin

Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K., Miyata, M., Yamazoe, Y., Takamura, T., Kaneko, S., & Fujimura, A. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02462.x · Cited by 108 · see citing works

Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase

Fujino, H., Saito, T., Ogawa, S.-I., & Kojima, J. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.10.0009 · Cited by 104 · see citing works

Perspectives of the non-statin hypolipidemic agents

Rozman, D., & Monostory, K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.007 · Cited by 94 · see citing works

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

Kajinami, K., Takekoshi, N., Brousseau, M. E., & Schaefer, E. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.09.004 · Cited by 92 · see citing works

Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

Fujino, H., Saito, T., Tsunenari, Y., Kojima, J., & Sakaeda, T. (2004) · Xenobiotica · doi:10.1080/00498250400015319 · Cited by 98 · see citing works

ATP-dependent transport of statins by human and rat MRP2/Mrp2

Ellis, L. C. J., HAWKSWORTH, G. M., & Weaver, R. J. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.03.019 · Cited by 74 · see citing works

Hawthorn (Crataegus pinnatifida Bunge) leave flavonoids attenuate atherosclerosis development in apoE knock-out mice

Dong, P., Pan, L., Zhang, X., Zhang, W., Wang, X., Jiang, M., Chen, Y., Duan, Y., Wu, H., Xu, Y., et al. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.01.040 · Cited by 69 · see citing works

An Improved Larock Synthesis of Quinolines via a Heck Reaction of 2-Bromoanilines and Allylic Alcohols

Stone, M. T. (2011) · Organic Letters · doi:10.1021/ol200579a · Cited by 65 · see citing works

Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells

Wang, J., Tokoro, T., Matsui, K., Higa, S., & Kitajima, I. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.12.003 · Cited by 62 · see citing works

Pitavastatin: efficacy and safety in intensive lipid lowering

Hayashi, T., Yokote, K., Saito, Y., & Iguchi, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2315 · Cited by 62 · see citing works

Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea

Kim, J., Lee, H. S., & Lee, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0799-4 · Cited by 61 · see citing works

Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines

Otahal, A., Aydemir, D., Tomasich, E., & Minichsdorfer, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-57707-2 · Cited by 58 · see citing works

New evidence on pitavastatin: efficacy and safety in clinical studies

Teramoto, T., Shimano, H., Yokote, K., & Urashima, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003641990 · Cited by 58 · see citing works

Pharmacogenomics of Statin Responsiveness

Kajinami, K., Akao, H., Polisecki, E. Y., & Schaefer, E. J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.011 · Cited by 58 · see citing works

Successful Treatment of Acute Lung Injury with Pitavastatin in Septic Mice: Potential Role of Glucocorticoid Receptor Expression in Alveolar Macrophages

Takano, K.-I., Yamamoto, S., Tomita, K., Takashina, M., Yokoo, H., Matsuda, N., Takano, Y., & Hattori, Y. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.171462 · Cited by 54 · see citing works

Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines.

Tsuboi, Y., Kurimoto, M., Nagai, S., Hayakawa, Y., Kamiyama, H., Hayashi, N., Kitajima, I., & Endo, S. (2009) · Journal of Neurosurgery · doi:10.3171/2008.8.jns17648 · Cited by 54 · see citing works

Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging strategies

Elkin, R. G. (2007) · World s Poultry Science Journal · doi:10.1017/s0043933907001249 · Cited by 50 · see citing works

Statins and Neuroprotection: Basic Pharmacology Needed

Wood, W. G., Mΰller, W. E., & Eckert, G. P. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8647-3 · Cited by 46 · see citing works

An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents

Boyapelly, K., Hemalatha, K., Pal, R., Matada, G. S. P., Hosamani, K. R., Aayishamma, I., & Aishwarya, N. V. S. S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116561 · Cited by 43 · see citing works

Interaction of fluvastatin with the liver-specific Na+-dependent taurocholate cotransporting polypeptide (NTCP)

Greupink, R., Dillen, L., Monshouwer, M., Huisman, M. T., & Rüssel, F. G. M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.09.009 · Cited by 43 · see citing works

Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study

Kawashiri, M.-A., Nohara, A., Tada, H., Mori, M., Tsuchida, M., Katsuda, S., Inazu, A., Kobayashi, J., Koizumi, J., Mabuchi, H., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100396 · Cited by 43 · see citing works

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

Wen, J.-L., & Xiong, Y. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01071.x · Cited by 40 · see citing works

A lipophilic statin, pitavastatin, suppresses inflammation‐associated mouse colon carcinogenesis

Yasui, Y., Suzuki, R., Miyamoto, S., Tsukamoto, T., Sugie, S., Kohno, H., & Tanaka, T. (2007) · International Journal of Cancer · doi:10.1002/ijc.22976 · Cited by 40 · see citing works

Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study

Takashima, H., Ozaki, Y., Yasukawa, T., Waseda, K., Asai, K., Wakita, Y., Kuroda, Y., Kosaka, T., Kuhara, Y., & Ito, T. (2007) · Circulation Journal · doi:10.1253/circj.71.1678 · Cited by 39 · see citing works

Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting

Yokoyama, T., Miyauchi, K., Kurata, T., Satoh, H., & Daida, H. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.039 · Cited by 39 · see citing works

Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

Hu, M., & Tomlinson, B. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.851667 · Cited by 37 · see citing works

Pitavastatin suppressed liver cancer cells in vitro and in vivo

Zhang, W.-J., He-yi, Y., Xie, X., Zheng, Z., Zhu, H.-L., & Jiang, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106906 · Cited by 36 · see citing works

A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan

Saito, M., Hirata‐Koizumi, M., Urano, T., Miyake, S., & Hasegawa, R. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00605.x · Cited by 33 · see citing works

Statins: can the new generation make an impression?

Rosenson, R. S. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.2.269 · Cited by 35 · see citing works

Cyclopropyl Scaffold: A Generalist for Marketed Drugs

Sun, M., Li, H., Ba, M.-Y., Cheng, W., Zhu, H., & Duan, Y. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200729161150 · Cited by 33 · see citing works

Short-term Effects of Pitavastatin on Biochemical Markers of Bone Turnover in Patients with Hypercholesterolemia

Majima, T., Shimatsu, A., Komatsu, Y., Satoh, N., Fukao, A., Ninomiya, K., Matsumura, T., & Nakao, K. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.0419 · Cited by 33 · see citing works

Effect of Pitavastatin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Nondiabetic Mild Chronic Kidney Disease

Nakamura, T., Sugaya, T., Kawagoe, Y., Suzuki, T., Inoue, T., & Node, K. (2006) · American Journal of Nephrology · doi:10.1159/000091956 · Cited by 32 · see citing works

Atherosclerosis: Current Status of Prevention and Treatment

Whayne, T. F. (2011) · International Journal of Angiology · doi:10.1055/s-0031-1295520 · Cited by 31 · see citing works

Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

Truong, W. R., Schafer, J. J., & Short, W. R. (2015) · PubMed Central · Cited by 31 · see citing works

Dose-Dependent Effect of Pitavastatin on VEGF and Angiogenesis in a Mouse Model of Choroidal Neovascularization

Zambarakji, H., Nakazawa, T., Connolly, E. J., Lane, A. M., Mallemadugula, S., Kaplan, M., Michaud, N. A., Hafezi‐Moghadam, A., Gragoudas, E. S., & Miller, J. W. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0855 · Cited by 30 · see citing works

Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: screening based on pharmacological and physiological properties

Pandya, J. D., Musyaju, S., Modi, H. R., Okada-Rising, S. L., Bailey, Z. S., Scultetus, A. H., & Shear, D. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04908-2 · Cited by 27 · see citing works

Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma

Iwahashi, N., Ikezaki, M., Fujimoto, M., Komohara, Y., Fujiwara, Y., Yamamoto, M., Mizoguchi, M., Matsubara, K., Watanabe, Y., Matsuzaki, I., et al. (2021) · Cancers · doi:10.3390/cancers13205251 · Cited by 26 · see citing works

Pitavastatin: evidence for its place in treatment of hypercholesterolemia

Alagona, P. (2010) · Core evidence · doi:10.2147/ce.s8008 · Cited by 26 · see citing works

Photostability of pitavastatin—A novel HMG-CoA reductase inhibitor

Grobelny, P. J., Viola, G., Vedaldi, D., Dall’Acqua, F., Gliszczyńska‐Świgło, A., & Mielcarek, J. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.10.004 · Cited by 26 · see citing works

Influence of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors on Ubiquinone Levels in Rat Skeletal Muscle and Heart: Relationship to Cytotoxicity and Inhibitory Activity for Cholesterol Synthesis in Human Skeletal Muscle Cells

Yamazaki, H., Suzuki, M., Aoki, T., Morikawa, S., Maejima, T., Sato, F., Sawanobori, K., Kitahara, M., Kodama, T., & Saitō, Y. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.295 · Cited by 25 · see citing works

Pitavastatin and HDL: Effects on plasma levels and function(s)

Pirillo, A., & Catapano, A. L. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.001 · Cited by 24 · see citing works

Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells

Wang, J., Xu, Z., Kitajima, I., & Wang, Z. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.10.034 · Cited by 24 · see citing works

Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes

Galgóczy, L., Lukács, G., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2010) · Acta Biologica Hungarica · doi:10.1556/abiol.61.2010.3.11 · Cited by 23 · see citing works

Mesoporous MCM‐41 Silica Supported Pyridine Nanoparticle: A Highly Efficient, Recyclable Catalyst for Expeditious Synthesis of Quinoline Derivatives through Domino Approach

Mal, K., Chatterjee, S., Bhaumik, A., & Mukhopadhyay, C. (2019) · ChemistrySelect · doi:10.1002/slct.201803708 · Cited by 23 · see citing works

Are Statins Applicable for the Prevention and Treatment of Zygomycosis?

Galgóczy, L., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2009) · Clinical Infectious Diseases · doi:10.1086/600825 · Cited by 22 · see citing works

Statins as antifungal agents

Galgóczy, L. (2011) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v1.i1.4 · Cited by 21 · see citing works

Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia

Gotto, A. M., & Moon, J. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.82 · Cited by 20 · see citing works

Pitavastatin inactivates NF-kappaB and decreases IL-6 production through Rho kinase pathway in MCF-7 cells.

Wang, J., & Kitajima, I. (2007) · PubMed · Cited by 20 · see citing works

Fruit and vegetable peels: Paving the way towards the development of new generation therapeutics.

Parmar, H. S., Dixit, Y., & Kar, A. (2010) · PubMed · Cited by 20 · see citing works

Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology (TRUTH Study)

Nozue, T., Yamamoto, S., Tohyama, S., Umezawa, S., Kunishima, T., Sato, A., Miyake, S., Takeyama, Y., Morino, Y., Yamauchi, T., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0593 · Cited by 19 · see citing works

Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers

Kokudai, M., Inui, N., Takeuchi, K., Sakaeda, T., Kagawa, Y., & Watanabe, H. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009332435 · Cited by 18 · see citing works

One‐Pot Synthesis of 4‐Substituted 1H‐[1,2,3]triazolo[4,5‐c]quinolines Through CuO‐Promoted Tandem Cyclization Reactions of (E)‐3‐(2‐Bromoaryl)‐1‐arylprop‐2‐en‐1‐ones with Sodium Azide

Li, K., Chen, J., Li, J., Chen, Y., Qu, J., Guo, X., Chen, C., & Chen, B. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201300924 · Cited by 17 · see citing works

Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies

Di, B., Su, M., Yu, F., Lan-jin, Q., Zhao, L., Cheng, M.-C., & He, L.-P. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.04.036 · Cited by 17 · see citing works

Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts

Viola, G., Grobelny, P. J., Linardi, M. A., Salvador, A., Dall’Acqua, S., Sobotta, Ł., Mielcarek, J., Dall’Acqua, F., Vedaldi, D., & Basso, G. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0772-4 · Cited by 17 · see citing works

Integrated Backscatter and Intima-Media Thickness of the Thoracic Aorta Evaluated by Transesophageal Echocardiography in Hypercholesterolemic Patients: Effect of Pitavastatin Therapy

Ono, K., Kawasaki, M., Tanaka, R., Segawa, T., Matsuo, H., Watanabe, S., Takemura, G., & Minatoguchi, S. (2008) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2008.08.011 · Cited by 16 · see citing works

Degradation Pathway for Pitavastatin Calcium by Validated Stability Indicating UPLC Method

Gomas, A. R., Ram, P. R., Srinivas, N., & Sriramulu, J. (2010) · American Journal of Analytical Chemistry · doi:10.4236/ajac.2010.12011 · Cited by 16 · see citing works

An Injectable Gel Platform for the Prolonged Therapeutic Effect of Pitavastatin in the Management of Hyperlipidemia

Xiang, N., Xu, Z., He, X., Zhang, Y. X., Zhang, J., Zhang, Z., Sun, X., Gong, T., & Fu, Y. S. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.12.002 · Cited by 15 · see citing works

Effects of Rosuvastatin and Pitavastatin on Ischemia-Induced Myocardial Stunning in Dogs

Satoh, K., Takaguri, A., Itagaki, M., Kano, S., & Ichihara, K. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08017fp · Cited by 15 · see citing works

Downregulation of survivin expression and elevation of caspase-3 activity involved in pitavastatin-induced HepG 2 cell apoptosis

Wang, J., Xu, Z., & Zhang, M. (2007) · Oncology Reports · doi:10.3892/or.18.2.383 · Cited by 14 · see citing works

Statin pharmacogenomics: what have we learned, and what remains unanswered?

Kajinami, K., Okabayashi, M., Sato, R., Polisecki, E. Y., & Schaefer, E. J. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191914.54439.b7 · Cited by 14 · see citing works

Statin response and pharmacokinetics variants

Kajinami, K., Masuya, H., Hoshiba, Y., Takeda, K., Sato, R., Okabayashi, M., & Schaefer, E. J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.8.1291 · Cited by 14 · see citing works

Xenosensors CAR and PXR at Work: Impact on Statin Metabolism

Marino, M., di Masi, A., Trezza, V., Pallottini, V., Polticelli, F., & Ascenzi, P. (2011) · Current Drug Metabolism · doi:10.2174/138920011795101859 · Cited by 13 · see citing works

Determination of Pitavastatin in Human Plasma by LC–MS–MS

Shentu, J., Xu, X., Liu, J., Hu, X., Chen, J., Wu, L., Huang, M., & Zhou, H. (2009) · Chromatographia · doi:10.1365/s10337-009-1006-2 · Cited by 12 · see citing works

Pitavastatin and carbohydrate metabolism: what is the evidence?

Filippatos, T. D., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1165607 · Cited by 12 · see citing works

A Validated Stability-Indicative UPLC Method for Nilotinib Hydrochloride for the Determination of Process-Related and Degradation Impurities

KONDRA, S., Madireddy, V., Chilukuri, M., Papadasu, N., & Jonnalagadda, L. P. (2013) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmt134 · Cited by 11 · see citing works

Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials

Jiang, Z., Gong, R., Qiu, L., Wang, Q., Su, M., Liu, X.-J., Hu, M.-S., Lin, J., & Fang, D. (2014) · Clinical drug investigation · doi:10.1007/s40261-014-0215-0 · Cited by 8 · see citing works

Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence

Prado, Y., Aravena, D., Llancalahuén, F. M., Aravena, C., Eltit, F., Echeverría, C., Gatica, S., Riedel, C. A., & Simón, F. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-26163-3_2 · Cited by 10 · see citing works

LC–MS/MS assay for pitavastatin in human plasma and subsequent application to a clinical study in healthy Chinese volunteers

Yin, T., Liu, Q., Zhao, H., Zhao, L., Liu, H., Li, M., Cui, M., & Ren, W. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.07.002 · Cited by 9 · see citing works

Pitavastatina: una nueva alternativa en el tratamiento de la dislipemia

Rodríguez, Á. D., Cumplido, A. S., González, D. F., Arroyo, L. A. R., Herreros, F. J. G.-N., Olea, S. D. A., Rodríguez, I. L., Royo, J. M. P., Villar, J. C. M., del arco, J. P., et al. (2011) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.10.005 · Cited by 9 · see citing works

Daily consumption of black soybean (Glycine max L.) seed coat polyphenols attenuates dyslipidemia in apolipoprotein E-deficient mice

Tanaka, W., Matsuyama, H., Yokoyama, D., Yamashita, Y., Ashida, H., Sakono, M., & Sakakibara, H. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104054 · Cited by 9 · see citing works

Stability-indicating liquid chromatographic method for analysis of pitavastatin calcium in tablet dosage forms

Panchal, H. J., & Suhagia, B. N. (2011) · Acta Chromatographica · doi:10.1556/achrom.23.2011.1.5 · Cited by 9 · see citing works

Impact of Genetic Polymorphisms on the Efficacy of HMG-CoA Reductase Inhibitors

Hutz, M. H., & Fiegenbaum, M. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808030-00003 · Cited by 9 · see citing works

Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity

Nakaoka, T., Kaneko, K., Irie, S., Mawatari, A., Igesaka, A., Uetake, Y., Ochiai, H., Niwa, T., Yamano, E., Wada, Y., et al. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100449 · Cited by 8 · see citing works

Radiosynthesis of novel pitavastatin derivative ([18F]PTV‐F1) as a tracer for hepatic OATP using a one‐pot synthetic procedure

Kimura, H., Yagi, Y., Arimitsu, K., Maeda, K., Ikejiri, K., Takano, J., Kusuhara, H., Kagawa, S., Ono, M., Sugiyama, Y., et al. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3464 · Cited by 8 · see citing works

Mini-Review on the Efficacy and Safety of Pitavastatin

Ramadan, A., & Elnour, A. A. (2022) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_455_21 · Cited by 6 · see citing works

Ultra-High Performance Method on Superficially Porous Stationary Phase for the Determination of Related Substances in Pitavastatin Calcium by HPLC

Hariram, B., Kumar, R., Anireddy, J. S., Rao, D. V., Kalyanaraman, L., & Srinivas, K. (2015) · Chromatographia · doi:10.1007/s10337-015-2922-y · Cited by 6 · see citing works

Development and validation of RP-HPLC method for pitavastatin calcium in bulk and formulation using experimental design

Vinod, R., Jani, G. K., Sen, A. K., Sailor, G. U., & Sutariya, V. B. (2019) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2019.91010 · Cited by 6 · see citing works

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

Grice, B. A., & Elmendorf, J. S. (2017) · US Endocrinology · doi:10.17925/use.2017.13.02.63 · Cited by 6 · see citing works

Rapid and selective determination of pitavastatin calcium in presence of its degradation products and co-formulated drug by first-derivative micelle-enhanced and synchronous fluorimetric methods

Fayed, A. S., Hegazy, M. A. M., Abbas, E. E., & Salama, N. N. (2016) · RSC Advances · doi:10.1039/c6ra20813d · Cited by 5 · see citing works

A New Ecological RP-HPLC Method for the Determination of Pitavastatin, Fenofibrate and Their Impurities in a Novel Fixed Dose Combination

Mohan, T. S. S. J., Jogia, H. A., & Mukkanti, K. (2022) · Chromatographia · doi:10.1007/s10337-021-04119-7 · Cited by 5 · see citing works

Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives

Cattaneo, D., Baldelli, S., Merlini, S., Zenoni, S., Perico, N., & Remuzzi, G. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.11.1553 · Cited by 5 · see citing works

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer

Ko, D., Park, S., Park, M.-S., Kim, S., Park, J. M., Seo, J., Nam, K. D., Kang, Y. K., Farrand, L., Jung, E., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00716-6 · Cited by 4 · see citing works

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing

Tristán-Flores, F. E., Casique‐Aguirre, D., Pliego-Arreaga, R., Cervantes‐Montelongo, J. A., García‐Gutiérrez, P., Acosta‐García, G., & Silva-Martínez, G. A. (2021) · F1000Research · doi:10.12688/f1000research.52168.2 · Cited by 4 · see citing works

The Isoprenoid Biosynthetic Pathway and Statins

Holstein, S. A. (2011) · The Enzymes · doi:10.1016/b978-0-12-415922-8.00012-4 · Cited by 4 · see citing works

Development, Characterization and In vitro Evaluation of Solid Dispersion Formulations of Low Aqueous Soluble BCS Class II Drug Pitavastatin with Poloxamer 407 and HPMC

Mikrani, I., Sarkar, M. R., Islam, M., Das, S. C., & Prattay, K. M. R. (2022) · Dhaka University Journal of Pharmaceutical Sciences · doi:10.3329/dujps.v20i3.59798 · Cited by 4 · see citing works

Comparison of the anticancer effects of various statins on canine oral melanoma cells

Ishikawa, T., Irie, N., Tashiro, J., Osaki, T., Warita, T., Warita, K., & Naito, M. (2023) · Veterinary and Comparative Oncology · doi:10.1111/vco.12946 · Cited by 4 · see citing works

Pitavastatin in the Management of Hypercholesterolemia

Nomura, S. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2690 · Cited by 4 · see citing works

A Rh(II)-Catalyzed Atropisomer Selective Ring Expansion of 3-Aryl Indoles to 4-Aryl Quinolines

Basilaia, M., Zanolini, R. J., Dogan, N. K., Rustin, G. J., Regganie, T., Susskind, N., Mao, Y., & Gustafson, J. L. (2026) · ACS Catalysis · doi:10.1021/acscatal.6c00603 · Cited by 3 · see citing works

New Drug Approvals: Pitavastatin: A New HMG-CoA Reductase Inhibitor

Wensel, T. M., Waldrop, B. A., & Wensel, B. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m624 · Cited by 23 · see citing works

Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet®)

Yamazaki, H., Fujino, H., Kanazawa, M., Tamaki, T., Sato, F., Suzuki, M., & Kitahara, M. (2004) · Folia Pharmacologica Japonica · doi:10.1254/fpj.123.349 · Cited by 10 · see citing works

Efficacy and safety of pitavastatin

Ohira, M., Shirai, K., & Tatsuno, I. (2015) · Journal of symptoms and signs

Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia

Baker, W. L., & Datta, R. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0092-8 · Cited by 13 · see citing works

Pitavastatin

Duggan, S. T. (2012) · Drugs · doi:10.2165/11207180-000000000-00000 · Cited by 32 · see citing works